BioInnovation Institute
VC Fund
Copenhagen, Denmark
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
- Total investments:
- 92
- Last investment:
- Lead investor:
- 92%
Last updated:
For AI agents: llms.txt
Industries BioInnovation Institute invests in
Stages BioInnovation Institute invests in
Countries BioInnovation Institute invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $532k–$1.8M
- Pre-Seed
- $530k–$5.2M
- Convertible Note
- $495k–$1.6M
Investment Focus
Industry
- Biotechnology 49 (53%)
- Medical 33 (36%)
- Health Care 24 (26%)
- Therapeutics 16 (17%)
- Medical Device 13 (14%)
Stage
- Convertible Note 62 (67%)
- Pre-Seed 7 (8%)
- Seed 4 (4%)
- Debt Financing 4 (4%)
- Grant 2 (2%)
Country
- Denmark 56 (61%)
- Germany 3 (3%)
- Switzerland 2 (2%)
- United States 2 (2%)
- The Netherlands 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bobby Soni
Chief Business Officer
|
Chief Business Officer | Total investments: 40 | Find email | |
Casper Linnemann Erichsen
Communications lead
|
Communications lead | Total investments: 0 | Find email | |
Maj Hedtjärn
Entrepreneur in Residence
|
Entrepreneur in Residence | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Prenaital
|
Prenaital is an AI-driven healthcare company dedicated to revolutionizing maternal care by improving the detection and management of high-risk pregnancies. Their AI technology enhances the identification of at-risk pregnancies by 25-50% compared to traditional methods, enabling earlier and more accurate intervention. Prenaital's solutionspersonalize prenatal care by incorporating key patient factors like BMI, ethnicity, and age, ensuring equitable and high-quality care for all expecting mothers. Their mission is to provide accessible, scalable AI tools that empower healthcare providers to reduce pregnancy complications and improve outcomes for mothers and babies worldwide. | $1.6M / Seed / Sep 10, 2025 | |
METSYSTEM
|
METSYSTEM has a unique technology that can predict cancer metastasis and determine the best chemotherapy to treat it preventively. | $1.4M / Convertible Note / Mar 07, 2025 | |
Fuse Vectors
|
Fuse Vectors is disrupting the manufacturing process in order to provide universal access to gene therapy. | $5.2M / Pre-Seed / Feb 25, 2025 | |
|
Prenaital
|
Prenaital is an AI-driven healthcare company dedicated to revolutionizing maternal care by improving the detection and management of high-risk pregnancies. Their AI technology enhances the identification of at-risk pregnancies by 25-50% compared to traditional methods, enabling earlier and more accurate intervention. Prenaital's solutionspersonalize prenatal care by incorporating key patient factors like BMI, ethnicity, and age, ensuring equitable and high-quality care for all expecting mothers. Their mission is to provide accessible, scalable AI tools that empower healthcare providers to reduce pregnancy complications and improve outcomes for mothers and babies worldwide. | $553.1K / Pre-Seed / Aug 30, 2024 | |
Arcana Bio
|
ArcanaBio develops advanced diagnostics systems that enable low cast, rapid and scalable biomonitoring for health & wellbeing using biophotonics and AI | $554K / Seed / Aug 29, 2024 | |
NorFalk
|
NorFalk is a biotech company that produces sustainable surfactants for applications in consumer everyday products. | $1.4M / Convertible Note / Mar 07, 2024 | |
oasicare
|
Oasicare is dedicated to enhancing the health of women worldwide during and after childbirth. A medical device that reduces the chance of birth tears is the company's initial offering. | $540.3K / Convertible Note / Feb 29, 2024 | |
Polyceutix
|
Polyceutix aims to treat muscle-invasive bladder cancer by employing AASTY-TLR, a novel immunomodulatory substance developed at the nexus of immunology and materials science. The copolymer AASTY-TLR is injected into tumors, where it breaks down the membrane proteins and lipid bilayers into polymer-lipid particles. | $540.3K / Convertible Note / Feb 29, 2024 | |
Pharmista Technologies
|
Pharmista Technologies is on a mission to revolutionize women’s health by disrupting the pregnancy testing market. | $540.3K / Convertible Note / Feb 29, 2024 | |
Alea Quantum Technologies
|
Alea technologies provide server- and rack-based QRNG systems for bigger cyber security infrastructures and datacenters. | $540.3K / Convertible Note / Feb 29, 2024 | |
| See all 92 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BioInnovation Institute invest in?
BioInnovation Institute invests primarily in Biotechnology, Medical and Health Care startups, most often at Convertible Note and Pre-Seed stage. Most of the 92 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BioInnovation Institute's check size?
BioInnovation Institute typically joins rounds of $532k–$1.8M at Seed, $530k–$5.2M at Pre-Seed and $495k–$1.6M at Convertible Note. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioInnovation Institute participates in.
How do I contact BioInnovation Institute?
Public channels for BioInnovation Institute include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioInnovation Institute?
The team at BioInnovation Institute includes Bobby Soni (Chief Business Officer), Casper Linnemann Erichsen (Communications lead) and Maj Hedtjärn (Entrepreneur in Residence). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
